Free Trial
NASDAQ:CRBP

Corbus Pharmaceuticals Q1 2024 Earnings Report

Corbus Pharmaceuticals logo
$8.43 -0.57 (-6.33%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$8.47 +0.04 (+0.47%)
As of 08/8/2025 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corbus Pharmaceuticals EPS Results

Actual EPS
-$0.83
Consensus EPS
-$1.09
Beat/Miss
Beat by +$0.26
One Year Ago EPS
N/A

Corbus Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Corbus Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 7, 2024
Conference Call Time
7:00AM ET

Corbus Pharmaceuticals Earnings Headlines

William Blair Issues Pessimistic Estimate for CRBP Earnings
HC Wainwright Analysts Increase Earnings Estimates for CRBP
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Corbus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals (NASDAQ:CRBP), a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

View Corbus Pharmaceuticals Profile

More Earnings Resources from MarketBeat